Lonza (Switzerland) announced an agreement with GE Healthcare (USA) under which GE Healthcare will deliver a biologics facility to Lonza in Guangzhou (China).
As the facility is part of a larger biomanufacturing initiative between GE Healthcare and Guangzhou Development District (GDD). The new facility will give Lonza a strategic base in China to respond to growing demand for high-quality CDMO services in the country.
By working with GE Healthcare to develop the new facility, based on the KUBio platform, an off-the-shelf biologics factory, Lonza intends to offer its suite of antibody development services and manufacture GMP-certified batches by 2020. The two companies will work closely on the design of the 17,000 sq m site, which will include 6,500 sq m of lab space and one KUBio facility. The labs will house Lonza’s proprietary platforms for cell-line construction, as well as process development, cell banking and pilot labs. The KUBio unit will enable small-scale GMP manufacturing equipped with GE Healthcare’s single-use biomanufacturing technologies, including 1,000 and 2,000L bioreactors, combined with Lonza’s automation platforms for clinical and early-commercial supply.
The new facility will extend Lonza’s global biologics network that provides development and manufacturing services. In addition to the new Chinese site, the network comprises small-, mid- and large-scale assets in Switzerland, the United States, the UK, Spain and Singapore.
A strong scientific base and commercial instruments put into place by the Chinese authorities are encouraging their domestic companies developing innovative therapies for the global market, as well as multinationals with manufacturing requirements in the country.